These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15452367)

  • 21. [Application of ultra-short gonadotropin-releasing hormone agonist protocol in controlled ovarian hyperstimulation].
    Zhao X; Zhang L; Gong S
    Zhonghua Fu Chan Ke Za Zhi; 1997 Oct; 32(10):589-92. PubMed ID: 9642373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development.
    Ergür AR; Yergök YZ; Ertekin A; Küçük T; Müngen E; Tütüncü L
    J Reprod Med; 1998 Mar; 43(3):185-90. PubMed ID: 9564642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome.
    Wada I; Matson PL; Troup SA; Lieberman BA
    J Assist Reprod Genet; 1995 Apr; 12(4):252-7. PubMed ID: 7580021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo reactivity of the ovarian vascular bed to noradrenaline and carbachol during ovarian hyperstimulation syndrome.
    Oriowo MA
    Med Princ Pract; 2004; 13(3):115-21. PubMed ID: 15073421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a gonadotropin-releasing hormone agonist and gonadotropins on ovarian follicles in cynomolgus monkey: a model for human ovarian hyperstimulation.
    Lefèvre B; Gougeon A; Nomé F; Testart J
    Fertil Steril; 1991 Jul; 56(1):119-25. PubMed ID: 1906016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit.
    Pride SM; Yuen BH; Moon YS; Leung PC
    Am J Obstet Gynecol; 1986 May; 154(5):1155-60. PubMed ID: 3085504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotropin-releasing hormone agonists induce meiotic maturation and degeneration of oocytes in the in vitro perfused rabbit ovary.
    Yoshimura Y; Nakamura Y; Yamada H; Nanno T; Ubukata Y; Ando M; Suzuki M
    Fertil Steril; 1991 Jan; 55(1):177-83. PubMed ID: 1898889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of GnRH agonist and menotropin therapy on lipoprotein metabolism.
    Goldman GA; Ovadia J; Fisch B
    Gynecol Endocrinol; 1996 Jun; 10(3):159-64. PubMed ID: 8862490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experemental modeling of ovary hyperstimulation syndrome in test animals].
    Aĭziatulova ÉM; Chaĭka AV; Nosenko EN; Smol'ianinova EI; Volina VV; Aĭziatulova DR
    Lik Sprava; 2013 Sep; (6):96-104. PubMed ID: 25510097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian hyperstimulation after administration of triptorelin therapy to a patient with polycystic ovary syndrome.
    Campo S; Bezzi I; Garcea N
    Fertil Steril; 2000 Jun; 73(6):1256-8. PubMed ID: 10856495
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome.
    Leung P; Ho Yuen B; Moon YS
    Am J Obstet Gynecol; 1983 Apr; 145(7):847-9. PubMed ID: 6404170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.
    Brett S; Yong PY; Thong KJ
    J Assist Reprod Genet; 2001 Jun; 18(6):353-6. PubMed ID: 11495415
    [No Abstract]   [Full Text] [Related]  

  • 33. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
    Goulding A; Gold E; Feng W
    Bone Miner; 1992 Aug; 18(2):143-52. PubMed ID: 1525595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary.
    Yarali H; Fleige-Zahradka BG; Yuen BH; McComb PF
    Fertil Steril; 1993 Mar; 59(3):657-61. PubMed ID: 8458471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
    Taskin MI; Topcu O; Yay A; Erken G; Balcioğlu E; Adali E; Hismiogulları AA
    Gynecol Endocrinol; 2015; 31(12):949-54. PubMed ID: 26369707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit.
    Teruel MJ; Carbonell LF; Llanos MC; Parrilla JJ; Abad L; Hernandez I
    Fertil Steril; 2002 Jun; 77(6):1256-60. PubMed ID: 12057737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe ovarian hyperstimulation: a case report and essentials of prevention and management.
    Scheele F; Hompes PG; Bernardus RE; Schoemaker J
    Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(3):187-92. PubMed ID: 1511766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian hyperstimulation caused by a gonadotropin agonist.
    Letterie GS
    Am J Obstet Gynecol; 2000 Mar; 182(3):747. PubMed ID: 10739547
    [No Abstract]   [Full Text] [Related]  

  • 39. An ectopic pregnancy masked by follicular initiation of gonadotropin-releasing hormone agonist for pituitary desensitization prior to in vitro fertilization.
    Hemmings R; Biljan MM; Dean N; Tan SL
    J Assist Reprod Genet; 1998 Mar; 15(3):161-3. PubMed ID: 9547694
    [No Abstract]   [Full Text] [Related]  

  • 40. Ovarian hyperstimulation syndrome associated with the use of the gonadotropin-releasing hormone agonist leuprolide acetate.
    Droesch K; Barbieri RL
    Fertil Steril; 1994 Jul; 62(1):189-90. PubMed ID: 8005289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.